🇺🇸 FDA
Pipeline program

Empagliflozin

MMELIFT01

Unknown small_molecule completed

Quick answer

Empagliflozin for Non Alcoholic Fatty Liver Disease is a Unknown program (small_molecule) at MEDA Pharma GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
MEDA Pharma GmbH & Co. KG
Indication
Non Alcoholic Fatty Liver Disease
Phase
Unknown
Modality
small_molecule
Status
completed

Clinical trials